Investor Presentaiton

Phase 3 Phase 2 Phase 1 +AHR Antagonist*^ Solid Tumors +Anti-CCR8^ Solid Tumors + Anti-ILT4^ Solid Tumors +Anti-NKG2A^ Solid Tumors +AR LDD 1L, 2L mCRPC Oncology +Claudin 18.2 ADC Solid Tumors +DGK Inhibitor Solid Tumors +JNK Inhibitor Solid Tumors +Helios CELMOD Solid Tumors +MAGEA4/8 TCER* Solid Tumors +Anti-CTLA-4 NF ProbodyⓇ Solid Tumors Anti-Fucosyl GM1^ RR SCLC + Anti-IL-8^ Solid Tumors +BET Inhibitor (BMS-986378)^ Solid Tumors +farletuzumab ecteribulin Solid Tumors nivolumab+relatlimab Stage IV 1L NSCLC nivolumab+relatlimab 1L HCC nivolumab+relatlimab 2L+ HCC (Post-TKI) +SHP2 Inhibitor^ Solid Tumors +TGFB Inhibitor^ Solid Tumors +TIGIT Bispecific Solid Tumors +repotrectinib NTRK Pan-Tumor +alnuctamab RR MM +Anti-SIRPa BMS Pipeline Hematology +BET Inhibitor (BMS-986378)^ RR NHL Immunology +Anti-CD40 Autoimmune Disease afimetoran CLE +GPRC5D CAR T RR MM +CD19 NEX T Severe Refractory SLE +IL2-CD25 Autoimmune Disease +PKCe Inhibitor Autoimmune Disease Data as of September 14th, 2023 Cardiovascular +FXla Inhibitor Thrombotic Disorders Neuroscience +Anti-MTBR-Tau Alzheimer's Disease +elF2b Activator Neuroscience +FAAH/MGLL Dual Inhibitor Neuroscience +BTK Inhibitor Neuroscience Hematologic Malignancies CK1a Degrader Hematologic Malignancies +BCMA NKE RR MM +BCL6 LDD Lymphoma BET Inhibitor (BMS-986158) Hematologic Malignancies +golcadomide^ RR NHL +BET Inhibitor (BMS-986158) 1L MF ABECMA 1-4L+ MM BREYANZI 3L+ CLL golcadomide^ 1L DLBCL +CD33 NKE RR MM RR MZL BREYANZI +afimetoran SLE SOTYKTU Alopecia Areata BREYANZI RR MCL SOTYKTU DLE +TYK2 Inhibitor (BMS-986322) REBLOZYL A-Thalassemia ONUREG MDS BREYANZI RR FL Mod-to-Severe Psoriasis +MYK-224 OHCM +danicamtiv Dilated Cardiomyopathy CAMZYOS HFPEF +SC nivolumab + rHuPH20 (multi-indications) 2L RCC OPDIVO Adjuvant HCC OPDIVO Peri-adjuvant MIUC OPDIVO Stage IB-IIIA Adjuvant NSCLC* OPDIVO+YERVOY 1L HCC OPDIVO+YERVOY 1L MIUC OPDIVO+YERVOY St3 Unresectable NSCLC OPDUALAG Adjuvant Melanoma OPDUALAG 2L/3L+ MSS MCRC +iberdomide 2L+ MM iberdomide Post-ASCT Maintenance NDMM +mezigdomide 2L+ MM Vd INREBIC MF REBLOZYL 1L TD MF Associated Anemia REBLOZYL 1L NTD MDS Associated Anemia Ill Bristol Myers Squibb™ OPDIVO OPDIVO + YERVOY 1L+ MSI High CRC +SC nivolumab + relatlimab + rHuPH20 Peri-adjuvant NSCLC mezigdomide 2L+ MM Kd 1L Melanoma * Partner-run study; ^ Trials exploring various combinations; +NME leading indication; # BMS territory SOTYKTU SOTYKTU +cendakimab Eosinophilic Esophagitis SLE +LPA1 Antagonist IPF LPA1 Antagonist PPF SOTYKTU Psoriatic Arthritis Sjögren's Syndrome ZEPOSIA Crohn's Disease +obexelimab*# IgG4-Related Disease +milvexian Secondary Stroke Prevention* milvexian Acute Coronary Syndrome* milvexian Atrial Fibrillation* CAMZYOS nHCM Not for Product Promotional Use

View entire presentation